{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:03:40Z","timestamp":1790492620973,"version":"4.1.0"},"reference-count":201,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.<\/jats:p>","DOI":"10.3390\/cancers12020318","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T10:51:07Z","timestamp":1580295067000},"page":"318","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["HDAC6\u2014An Emerging Target Against Chronic Myeloid Leukemia?"],"prefix":"10.3390","volume":"12","author":[{"given":"H\u00e9l\u00e8ne","family":"Losson","sequence":"first","affiliation":[{"name":"Laboratoire de Biologie Mol\u00e9culaire et Cellulaire du Cancer, H\u00f4pital Kirchberg 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-9538","authenticated-orcid":false,"given":"Michael","family":"Schnekenburger","sequence":"additional","affiliation":[{"name":"Laboratoire de Biologie Mol\u00e9culaire et Cellulaire du Cancer, H\u00f4pital Kirchberg 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Dicato","sequence":"additional","affiliation":[{"name":"Laboratoire de Biologie Mol\u00e9culaire et Cellulaire du Cancer, H\u00f4pital Kirchberg 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Diederich","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and outcome of 2904 CML patients from the EUTOS population-based registry","volume":"31","author":"Hoffmann","year":"2017","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: Incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1172\/JCI31771","article-title":"Discovery of the Philadelphia chromosome: A personal perspective","volume":"117","author":"Nowell","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia chromosome in leukemogenesis","volume":"35","author":"Kang","year":"2016","journal-title":"Chin. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.3139re6","article-title":"ABL tyrosine kinases: Evolution of function, regulation, and specificity","volume":"3","author":"Colicelli","year":"2010","journal-title":"Sci. Signal."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1242\/jcs.175521","article-title":"Multifunctional Abl kinases in health and disease","volume":"129","author":"Khatri","year":"2016","journal-title":"J. Cell Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/MCB.01454-13","article-title":"The capable ABL: What is its biological function?","volume":"34","author":"Wang","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"ref_11","first-page":"2343","article-title":"The BCR gene and philadelphia chromosome-positive leukemogenesis","volume":"61","author":"Laurent","year":"2001","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.leu.2402814","article-title":"Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome","volume":"17","author":"Drummond","year":"2003","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/sj.leu.2403079","article-title":"BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis","volume":"17","author":"Schultheis","year":"2003","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Leonard, D.G.B. (2007). Myeloproliferative disorders and myelodysplastic syndromes. Molecular Pathology in Clinical Practice, Springer.","DOI":"10.1007\/978-0-387-33227-7"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2141.2005.05468.x","article-title":"Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells","volume":"129","author":"Withey","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_16","first-page":"3603","article-title":"Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase","volume":"53","author":"Beran","year":"1993","journal-title":"Cancer Res."},{"key":"ref_17","first-page":"247","article-title":"Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia","volume":"11","author":"Yaghmaie","year":"2008","journal-title":"Arch. Iranian Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.leu.2404580","article-title":"A novel BCR-ABL fusion transcript (e18a2) in a child with chronic myeloid leukemia","volume":"21","author":"Beverloo","year":"2007","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood.V88.6.2236.bloodjournal8862236","article-title":"A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia","volume":"88","author":"Hochhaus","year":"1996","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","article-title":"Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia","volume":"17","author":"Deininger","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1101\/gad.12.10.1415","article-title":"Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway","volume":"12","author":"Dai","year":"1998","journal-title":"Genes Dev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Molls, M., Vaupel, P., Nieder, C., and Anscher, M.S. (2009). Tumor Growth and Cell Proliferation. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies, Springer.","DOI":"10.1007\/978-3-540-74386-6"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1126\/science.7939633","article-title":"Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family","volume":"266","author":"Reuther","year":"1994","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia--advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1182\/blood-2005-08-3399","article-title":"A common phosphotyrosine signature for the Bcr-Abl kinase","volume":"107","author":"Goss","year":"2006","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"612567","DOI":"10.1155\/2015\/612567","article-title":"Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias","volume":"2015","author":"Morotti","year":"2015","journal-title":"Adv. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1038\/sj.emboj.7600827","article-title":"Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8","volume":"24","author":"Shin","year":"2005","journal-title":"EMBO J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1128\/MCB.01563-08","article-title":"Evidence for regulation of mitotic progression through temporal phosphorylation and dephosphorylation of CK2alpha","volume":"29","author":"Derksen","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1038\/sj.onc.1204779","article-title":"Crk family adaptors-signalling complex formation and biological roles","volume":"20","author":"Feller","year":"2001","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2009.00844.x","article-title":"The roles of Dok family adapters in immunoreceptor signaling","volume":"232","author":"Mashima","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_31","first-page":"1097","article-title":"The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl","volume":"60","author":"Lionberger","year":"2000","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1182\/blood.V95.3.776.003k23_776_782","article-title":"Adaptor proteins CRK and CRKL associate with the serine\/threonine protein kinase GCKR promoting GCKR and SAPK activation","volume":"95","author":"Shi","year":"2000","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/j.1460-2075.1994.tb06319.x","article-title":"Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway","volume":"13","author":"Puil","year":"1994","journal-title":"EMBO J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1093\/emboj\/20.23.6793","article-title":"Tyrosine phosphorylation of Grb2 by Bcr\/Abl and epidermal growth factor receptor: A novel regulatory mechanism for tyrosine kinase signaling","volume":"20","author":"Li","year":"2001","journal-title":"EMBO J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.18632\/oncotarget.2072","article-title":"LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia","volume":"5","author":"Frietsch","year":"2014","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.18632\/oncotarget.3083","article-title":"An update on the LIM and SH3 domain protein 1 (LASP1): A versatile structural, signaling, and biomarker protein","volume":"6","author":"Orth","year":"2015","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1002\/pmic.200600109","article-title":"Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells","volume":"6","author":"Liang","year":"2006","journal-title":"Proteomics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-017-0418-y","article-title":"Paxillin: A crossroad in pathological cell migration","volume":"10","author":"Lopez","year":"2017","journal-title":"J. Hematol. Oncol"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"C1775","DOI":"10.1152\/ajpcell.00420.2006","article-title":"Obligatory role for phospholipase C-gamma(1) in villin-induced epithelial cell migration","volume":"292","author":"Wang","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/ncb2731","article-title":"FBXL2- and PTPL1-mediated degradation of p110-free p85beta regulatory subunit controls the PI(3)K signalling cascade","volume":"15","author":"Kuchay","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bbcan.2017.05.008","article-title":"Protein kinase D signaling in cancer: A friend or foe?","volume":"1868","author":"Roy","year":"2017","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cell.2006.11.047","article-title":"Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases","volume":"128","author":"Grimmler","year":"2007","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.biochi.2008.10.010","article-title":"p120-Ras GTPase activating protein (RasGAP): A multi-interacting protein in downstream signaling","volume":"91","author":"Pamonsinlapatham","year":"2009","journal-title":"Biochimie"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"13224","DOI":"10.1074\/jbc.M307456200","article-title":"Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and regulates migration and sprouting but not survival of endothelial cells","volume":"279","author":"Audero","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.4049\/jimmunol.169.10.5441","article-title":"Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors","volume":"169","author":"Freeburn","year":"2002","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2013.351","article-title":"PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis","volume":"28","author":"Berger","year":"2014","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1038\/s41598-017-03335-2","article-title":"Mechanical stability of talin rod controls cell migration and substrate sensing","volume":"7","author":"Rahikainen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"57117","DOI":"10.18632\/oncotarget.10986","article-title":"Ablation of human telomerase reverse transcriptase (hTERT) induces cellular senescence in gastric cancer through a galectin-3 dependent mechanism","volume":"7","author":"La","year":"2016","journal-title":"Oncotarget"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","article-title":"Immunological off-target effects of imatinib","volume":"13","author":"Zitvogel","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1684\/abc.2017.1233","article-title":"Treatment and molecular monitoring update in chronic myeloid leukemia management","volume":"75","author":"Sorel","year":"2017","journal-title":"Annales de biologie clinique"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1947601912458584","article-title":"Structure, regulation, signaling, and targeting of abl kinases in cancer","volume":"3","author":"Hantschel","year":"2012","journal-title":"Genes Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ddtec.2013.12.001","article-title":"New resistance mechanisms for small molecule kinase inhibitors of Abl kinase","volume":"11","author":"Modugno","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review","volume":"34","author":"An","year":"2010","journal-title":"Leukemia Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2217\/pgs-2017-0193","article-title":"Pharmacogenetics and the treatment of chronic myeloid leukemia: How relevant clinically? An update","volume":"19","author":"Ankathil","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"503","DOI":"10.18388\/abp.2013_2014","article-title":"Role of anti-apoptotic pathways activated by BCR\/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors","volume":"60","author":"Danisz","year":"2013","journal-title":"Acta Biochim. Polonica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bdq.2017.01.001","article-title":"Molecular techniques for the personalised management of patients with chronic myeloid leukaemia","volume":"11","author":"Alikian","year":"2017","journal-title":"Biomol. Detect. Quantif."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review","volume":"93","author":"Yang","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: The paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.2147\/DDDT.S85050","article-title":"Dasatinib for the treatment of chronic myeloid leukemia: Patient selection and special considerations","volume":"10","author":"Keskin","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_61","first-page":"23","article-title":"Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: Role of nilotinib","volume":"10","author":"Emole","year":"2016","journal-title":"Biol. Targets Ther."},{"key":"ref_62","first-page":"160","article-title":"Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects","volume":"7","author":"Ault","year":"2016","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4161\/cbt.28931","article-title":"SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells","volume":"15","author":"Bu","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: A clinical perspective and emerging treatment options","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1002\/cam4.2410","article-title":"Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors","volume":"8","author":"Etienne","year":"2019","journal-title":"Cancer Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Bixby, D., and Talpaz, M. (2009). Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematol. Am. Soc. Hematol. Educ. Program.","DOI":"10.1182\/asheducation-2009.1.461"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/epi.14.69","article-title":"Histone deacetylase 6 in health and disease","volume":"7","author":"Seidel","year":"2015","journal-title":"Epigenomics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2478\/folmed-2018-0030","article-title":"Mutations Associated with Imatinib Mesylate Resistance\u2014Review","volume":"60","author":"Linev","year":"2018","journal-title":"Folia Med. (Plovdiv.)"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia","volume":"9","author":"Loscocco","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2018.08.016","article-title":"Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis","volume":"104","author":"Fachi","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/leu.2015.42","article-title":"Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1","volume":"29","author":"Zabriskie","year":"2015","journal-title":"Leukemia"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Tang, L., Zhang, H., Peng, Y.Z., Li, C.G., Jiang, H.W., Xu, M., Mei, H., and Hu, Y. (2019). Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: An update network meta-analysis. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6039-9"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00277-018-3444-0","article-title":"Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: A case report and literature review","volume":"98","author":"Park","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Losson, H., Schnekenburger, M., Dicato, M., and Diederich, M. (2016). Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer. Molecules, 21.","DOI":"10.3390\/molecules21111608"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13148-016-0224-3","article-title":"Sirtuin functions and modulation: From chemistry to the clinic","volume":"8","author":"Carafa","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13046-016-0461-5","article-title":"Sirtuins in metabolism, DNA repair and cancer","volume":"35","author":"Mei","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.2003.tb05964.x","article-title":"Histone deacetylases: Unique players in shaping the epigenetic histone code","volume":"983","author":"Thiagalingam","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): Characterization of the classical HDAC family","volume":"370","author":"Caron","year":"2003","journal-title":"Biochem. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"48246","DOI":"10.1074\/jbc.M408583200","article-title":"Role of the tetradecapeptide repeat domain of human histone deacetylase 6 in cytoplasmic retention","volume":"279","author":"Bertos","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/febs.12079","article-title":"Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes","volume":"280","author":"Li","year":"2013","journal-title":"FEBS J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1099\/jgv.0.000679","article-title":"Cellular defence or viral assist: The dilemma of HDAC6","volume":"98","author":"Zheng","year":"2017","journal-title":"J. Gen. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"12487","DOI":"10.1074\/jbc.M114.607580","article-title":"Histone deacetylase 6 (HDAC6) promotes the pro-survival activity of 14-3-3zeta via deacetylation of lysines within the 14-3-3zeta binding pocket","volume":"290","author":"Mortenson","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13238-014-0102-8","article-title":"Proteomic identification and functional characterization of MYH9, Hsc70, and DNAJA1 as novel substrates of HDAC6 deacetylase activity","volume":"6","author":"Zhang","year":"2015","journal-title":"Protein Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1074\/jbc.M117.795955","article-title":"Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity","volume":"293","author":"Wu","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"ra45","DOI":"10.1126\/scisignal.2002873","article-title":"Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms","volume":"5","author":"Beier","year":"2012","journal-title":"Sci. Signal."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"14045","DOI":"10.1074\/jbc.M115.640482","article-title":"Novel Interaction of Class IIb Histone Deacetylase 6 (HDAC6) with Class IIa HDAC9 Controls Gonadotropin Releasing Hormone (GnRH) Neuronal Cell Survival and Movement","volume":"290","author":"Xu","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"25748","DOI":"10.1074\/jbc.M111871200","article-title":"Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family","volume":"277","author":"Gao","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/1541-7786.MCR-16-0109","article-title":"HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth","volume":"14","author":"Medler","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/onc.2015.214","article-title":"Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer","volume":"35","author":"Chang","year":"2016","journal-title":"Oncogene"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/1541-7786.MCR-13-0040-T","article-title":"HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS","volume":"11","author":"Yang","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.bbrc.2013.11.007","article-title":"LC3B-II deacetylation by histone deacetylase 6 is involved in serum-starvation-induced autophagic degradation","volume":"441","author":"Liu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molcel.2014.04.028","article-title":"HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutSalpha","volume":"55","author":"Zhang","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.tibs.2015.05.001","article-title":"Peroxiredoxins: Guardians against oxidative stress and modulators of peroxide signaling","volume":"40","author":"Perkins","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1073\/pnas.0803749105","article-title":"HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation","volume":"105","author":"Parmigiani","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.it.2018.05.004","article-title":"HDAC6 at Crossroads of Infection and Innate Immunity","volume":"39","author":"Mayor","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"E3374","DOI":"10.1073\/pnas.1418603112","article-title":"Nuclear matrix-associated protein SMAR1 regulates alternative splicing via HDAC6-mediated deacetylation of Sam68","volume":"112","author":"Nakka","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1074\/jbc.M110.208884","article-title":"Regulation of Tat acetylation and transactivation activity by the microtubule-associated deacetylase HDAC6","volume":"286","author":"Huo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1093\/emboj\/cdf682","article-title":"In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation","volume":"21","author":"Matsuyama","year":"2002","journal-title":"EMBO J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"9514","DOI":"10.3390\/ijms14059514","article-title":"HDAC6 and ovarian cancer","volume":"14","author":"Haakenson","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41419-018-0688-5","article-title":"The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer\u2019s disease model","volume":"9","author":"Fan","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/nar\/gkv088","article-title":"MicroRNA-26a induced by hypoxia targets HDAC6 in myogenic differentiation of embryonic stem cells","volume":"43","author":"Lee","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/emboj.2011.466","article-title":"A novel GRK2\/HDAC6 interaction modulates cell spreading and motility","volume":"31","author":"Lafarga","year":"2012","journal-title":"EMBO J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"33156","DOI":"10.1074\/jbc.M113.472506","article-title":"Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration","volume":"288","author":"Williams","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Di Fulvio, S., Azakir, B.A., Therrien, C., and Sinnreich, M. (2011). Dysferlin interacts with histone deacetylase 6 and increases alpha-tubulin acetylation. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028563"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Tala, S.X., Chen, J., Zhang, L., Liu, N., Zhou, J., Li, D., and Liu, M. (2014). Microtubule stabilization by Mdp3 is partially attributed to its modulation of HDAC6 in addition to its association with tubulin and microtubules. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090932"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Yan, J., Seibenhener, M.L., Calderilla-Barbosa, L., Diaz-Meco, M.T., Moscat, J., Jiang, J., Wooten, M.W., and Wooten, M.C. (2013). SQSTM1\/p62 interacts with HDAC6 and regulates deacetylase activity. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076016"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1242\/bio.20147021","article-title":"Aggresome formation is regulated by RanBPM through an interaction with HDAC6","volume":"3","author":"Salemi","year":"2014","journal-title":"Biol. Open"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/j.1471-4159.2009.06102.x","article-title":"Tau--an inhibitor of deacetylase HDAC6 function","volume":"109","author":"Perez","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbrc.2013.05.076","article-title":"Tubulin polymerization promoting protein 1 (TPPP1) increases beta-catenin expression through inhibition of HDAC6 activity in U2OS osteosarcoma cells","volume":"436","author":"Schofield","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","article-title":"Histone deacetylase 6 in cancer","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1182\/bloodadvances.2018020065","article-title":"Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia","volume":"2","author":"Maharaj","year":"2018","journal-title":"Blood Adv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1038\/s41388-018-0379-9","article-title":"Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1172\/JCI85963","article-title":"HDAC6-mediated acetylation of lipid droplet-binding protein CIDEC regulates fat-induced lipid storage","volume":"127","author":"Qian","year":"2017","journal-title":"J. Clin. Invest."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.yexcr.2018.07.017","article-title":"HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR\/ABL1","volume":"370","author":"Bamodu","year":"2018","journal-title":"Exp. Cell Res."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Cosenza, M., and Pozzi, S. (2018). The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082337"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1021\/jm800093c","article-title":"Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles","volume":"51","author":"Dehmel","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/cb200134p","article-title":"A novel class of small molecule inhibitors of HDAC6","volume":"7","author":"Inks","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.bmc.2007.10.092","article-title":"Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs)","volume":"16","author":"Schafer","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cmdc.200800196","article-title":"Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors","volume":"4","author":"Schafer","year":"2009","journal-title":"ChemMedChem"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/npp.2013.207","article-title":"Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability","volume":"39","author":"Jochems","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/j.pain.0000000000000893","article-title":"HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy","volume":"158","author":"Krukowski","year":"2017","journal-title":"Pain"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1021\/acscentsci.7b00274","article-title":"HDAC6 Brain Mapping with [(18)F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination","volume":"3","author":"Strebl","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/jm301355j","article-title":"Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif","volume":"56","author":"Wagner","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1021\/jm8002894","article-title":"Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: A new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6","volume":"51","author":"Kozikowski","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1080\/07391102.2016.1231084","article-title":"Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations","volume":"35","author":"Bello","year":"2017","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.18632\/oncotarget.13738","article-title":"Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1021\/jm900850t","article-title":"Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides","volume":"52","author":"Olsen","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1021\/jm701606b","article-title":"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum","volume":"51","author":"Chen","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1039\/C5CC10301K","article-title":"Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors","volume":"52","author":"Diedrich","year":"2016","journal-title":"Chem. Commun. (Camb.)"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1021\/jm502011f","article-title":"Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors","volume":"58","author":"Lin","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.1021\/jm400385r","article-title":"Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform","volume":"56","author":"Blackburn","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bcp.2015.11.005","article-title":"4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90alpha chaperone activity against prostate cancer","volume":"99","author":"Seidel","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1021\/jm5008962","article-title":"Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors","volume":"57","author":"Tang","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.ejmech.2017.10.040","article-title":"Recent advances in the discovery of potent and selective HDAC6 inhibitors","volume":"143","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1021\/acsmedchemlett.9b00084","article-title":"Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors","volume":"10","author":"Liang","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1021\/jm070178x","article-title":"Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies","volume":"50","author":"Kozikowski","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.jmedchem.7b01404","article-title":"(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo","volume":"61","author":"Lee","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1021\/acs.jmedchem.9b00946","article-title":"Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models","volume":"62","author":"Shen","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1021\/acs.jmedchem.8b01090","article-title":"Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors","volume":"62","author":"Vogerl","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1021\/acs.jmedchem.8b01013","article-title":"Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity","volume":"61","author":"Porter","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1021\/acs.jmedchem.5b00317","article-title":"Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor","volume":"58","author":"Duan","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/cmdc.201200529","article-title":"Discovery of pyridone-based histone deacetylase inhibitors: Approaches for metabolic stability","volume":"8","author":"Cho","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"10226","DOI":"10.1039\/C5OB01509J","article-title":"Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells","volume":"13","author":"Liu","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.1021\/jm400564j","article-title":"Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer\u2019s disease","volume":"56","author":"Yu","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1021\/jm0497592","article-title":"Subtype selective substrates for histone deacetylases","volume":"47","author":"Heltweg","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"13162","DOI":"10.1073\/pnas.1608067113","article-title":"Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma","volume":"113","author":"Hideshima","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1021\/acs.jmedchem.7b01593","article-title":"Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors","volume":"61","author":"Sellmer","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1021\/jm401899x","article-title":"Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells","volume":"57","author":"Lee","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1021\/acs.orglett.8b01118","article-title":"Multicomponent Synthesis and Binding Mode of Imidazo[1,2 -a]pyridine-Capped Selective HDAC6 Inhibitors","volume":"20","author":"Mackwitz","year":"2018","journal-title":"Org. Lett."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"12005","DOI":"10.1073\/pnas.1515882112","article-title":"Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected]","volume":"112","author":"Lee","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"15704","DOI":"10.1073\/pnas.1313893110","article-title":"Development of a histone deacetylase 6 inhibitor and its biological effects","volume":"110","author":"Lee","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1021\/acs.jmedchem.5b01342","article-title":"Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer","volume":"59","author":"Yang","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.1021\/jm301098e","article-title":"Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth","volume":"55","author":"Bergman","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/acs.jmedchem.5b01493","article-title":"Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors","volume":"59","author":"Senger","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"ref_161","first-page":"851","article-title":"ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma","volume":"32","author":"Wang","year":"2018","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41420-018-0103-0","article-title":"Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule","volume":"4","author":"Zhang","year":"2018","journal-title":"Cell Death Discov"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejphar.2018.03.026","article-title":"A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer","volume":"828","author":"Dong","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3109\/10428194.2011.570821","article-title":"Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells","volume":"52","author":"Lin","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ijc.32169","article-title":"Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models","volume":"145","author":"Depetter","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1021\/jm301769u","article-title":"3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition","volume":"56","author":"Patil","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1016\/j.bmcl.2015.07.065","article-title":"Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia","volume":"25","author":"Muthyala","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1021\/jm7009217","article-title":"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors","volume":"50","author":"Itoh","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acsmedchemlett.5b00303","article-title":"Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function","volume":"6","author":"Segretti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bmcl.2008.11.081","article-title":"Sulfamides as novel histone deacetylase inhibitors","volume":"19","author":"Wahhab","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"17297","DOI":"10.1038\/s41598-018-35602-1","article-title":"CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus","volume":"8","author":"Choi","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2174\/1568026615666150825141330","article-title":"Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments","volume":"16","author":"Schnekenburger","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1042\/CS20160084","article-title":"The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease","volume":"130","author":"Batchu","year":"2016","journal-title":"Clin. Sci. (Lond.)"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4161\/cbt.28469","article-title":"Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells","volume":"15","author":"Rosik","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.bbamcr.2019.03.003","article-title":"Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo","volume":"1866","author":"Hsieh","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"21065","DOI":"10.1074\/jbc.M802786200","article-title":"Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition","volume":"283","author":"Shan","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1038\/emboj.2011.298","article-title":"Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin","volume":"30","author":"Kaluza","year":"2011","journal-title":"EMBO J."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","article-title":"Combining epigenetic drugs with other therapies for solid tumours\u2014Past lessons and future promise","volume":"17","author":"Morel","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/CMAR.S70358","article-title":"Potential of epigenetic therapies in the management of solid tumors","volume":"7","author":"Valdespino","year":"2015","journal-title":"Cancer Manag. Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/cancers5030919","article-title":"Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies","volume":"5","author":"Grassadonia","year":"2013","journal-title":"Cancers"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.biomaterials.2015.02.015","article-title":"Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors","volume":"51","author":"Wang","year":"2015","journal-title":"Biomaterials"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1021\/acs.jmedchem.9b00924","article-title":"Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases","volume":"63","author":"Brindisi","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.leukres.2012.02.026","article-title":"HDAC6 as a target for antileukemic drugs in acute myeloid leukemia","volume":"36","author":"Hackanson","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"29168","DOI":"10.1074\/jbc.M112.371120","article-title":"Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation","volume":"287","author":"Liu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.tips.2014.08.001","article-title":"Drugging the HDAC6-HSP90 interplay in malignant cells","volume":"35","author":"Kramer","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.canlet.2017.01.033","article-title":"HDAC6 deacetylates p53 at lysines 381\/382 and differentially coordinates p53-induced apoptosis","volume":"391","author":"Ryu","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2008-03-143644","article-title":"HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells","volume":"112","author":"Rao","year":"2008","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e01557","DOI":"10.7554\/eLife.01557","article-title":"Hdac6 regulates Tip60-p400 function in stem cells","volume":"2","author":"Chen","year":"2013","journal-title":"Elife"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.exphem.2016.02.007","article-title":"Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition","volume":"44","author":"Kuo","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Lernoux, M., Schnekenburger, M., Dicato, M., and Diederich, M. (2019). Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia. Biochem. Pharmacol.","DOI":"10.1016\/j.bcp.2019.113698"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_195","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1158\/1078-0432.CCR-11-0234","article-title":"HDAC inhibitors potentiate the activity of the BCR\/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR\/ABL+ leukemia cells in vitro and in vivo","volume":"17","author":"Nguyen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.7150\/thno.16139","article-title":"Depletion of gamma-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib","volume":"6","author":"Jin","year":"2016","journal-title":"Theranostics"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/sctm.18-0247","article-title":"Concise Review: Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit","volume":"8","author":"Zhang","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"14848","DOI":"10.1039\/C9CC08509B","article-title":"Plasticity in designing PROTACs for selective and potent degradation of HDAC6","volume":"55","author":"Yang","year":"2019","journal-title":"Chem. Commun. (Camb.)"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/2\/318\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:52:57Z","timestamp":1760172777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/2\/318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":201,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["cancers12020318"],"URL":"https:\/\/doi.org\/10.3390\/cancers12020318","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202001.0030.v1","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]}}}